What top creators are saying about ImmunityBio Inc.(IBRX)

Appeared in the performance-screen review without a specific investment thesis.

Bearish weekly divergence suggested a possible pullback, but the larger weekly trend remained constructive while the stock held its prior low near $6.65.

Dismissively described as a penny stock that the speaker's group had shorted years earlier; no current position or fresh thesis was stated.

Mentioned as a penny stock that the speaker’s group had shorted years earlier; no current position or recommendation was established.

Mentioned as a relevant asset in the investment context.

Experiencing significant upward momentum with substantial upside potential following preliminary reports of 400% sales growth for its product ANTIKVA and its perception as a potential 'cure for cancer'.

Shows a significant short interest of 121M shares against a free float of only 89M shares, indicating a high potential for a short squeeze, presenting a risky but potentially lucrative opportunity.

ANKTIVA, combined with a checkpoint inhibitor, showed statistically significant immune restoration and improved overall survival in non-small cell lung cancer (NSCLC) patients. A Phase 3 trial is underway to confirm these benefits, suggesting a potentially significant therapeutic advancement.

A speculative, long-term play that could reprice significantly higher if a new political administration prioritizes immune system-focused treatments over traditional cancer therapies.

Presents a high-risk, high-reward opportunity based on the potential FDA approval of its cancer drug, ANKTIVA. A successful approval could lead to a 100x return or more, making it a binary bet on the upcoming FDA decision.